Apidra received FDA approval in 2004 [1].
When did Apidra become available in the US?
Apidra's FDA approval in 2004 marked its entry into the U.S. market as a rapid-acting mealtime insulin [1].
What is Apidra used for?
Apidra is a synthetic rapid-acting insulin analog used to control high blood sugar in adults and children with diabetes mellitus [2]. It is intended for use at mealtime and may also be used for continuous subcutaneous insulin infusion via an insulin pump [2].
How does Apidra work?
Apidra works by lowering blood glucose. It is absorbed quickly into the bloodstream and begins to work faster than regular human insulin [3]. This rapid action helps manage post-meal blood sugar spikes [3].
What is the difference between Apidra and other insulins?
Apidra is a rapid-acting insulin, meaning it starts working within 15 minutes, peaks in about 1 hour, and lasts for 2 to 4 hours [3]. This differs from shorter-acting insulins like human regular insulin, which takes longer to start working, or long-acting insulins that provide basal coverage over many hours [3].
Who manufactures Apidra?
Apidra is manufactured by Sanofi [1].
What is Apidra's patent status?
Information on Apidra's specific patent expiration dates and any related patent challenges can be found by searching patent databases and resources like DrugPatentWatch.com [4]. Such details are crucial for understanding when generic or biosimilar versions might become available.